Sildenafil for Health & Longevity - Quick Reference Sheet

Sildenafil for Health & Longevity

Created on 09/26/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Grok 4 – Audit

Sildenafil is a prescription oral medication for erection difficulty and high blood pressure in the lung arteries. It helps blood vessels relax when a widen-vessel signal is present. Both uses are well studied in controlled trials. Record studies find fewer heart attacks, deaths, and dementia diagnoses among men prescribed it or similar ones, but only an association. Nitrate heart medicines and riociguat, combined with sildenafil, can drop blood pressure dangerously. (Full Review)

Protocol

As-needed erection regimen
50 mg orally
About 1 hour before sexual activity; adjustable to 25–100 mg; no more than once a day. Stimulation is required. Labeled start is 25 mg after age 65, with creatinine clearance under 30 mL/min, or hepatic impairment.
Lung-artery regimen
20 mg orally three times daily
Studied in women and men. Disease treatment for high lung-artery pressure, not a longevity schedule.
Off-label single daily dose
20–25 mg once daily
No named clinic standard is established; differs from the erection-trial regimen and the 12-week lung-artery regimen.
Time to effect
Erection facilitation
30–60 minutes
Often noticeable; sexual stimulation is required.
Useful window
About 4 hours
Half-life is 3–5 hours.
Heart, death, and dementia
Years
Where reported, associations reflect years of prescribing, not days of use.

Benefits

Contraindications
  • Organic nitrates and nitrites (nitrate heart medicines: nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, amyl nitrite): any form, regularly or intermittently; no safe gap is established
  • Guanylate cyclase stimulators (riociguat):
  • Known hypersensitivity to sildenafil
  • Resting blood pressure below 90/50 mmHg
  • Resting blood pressure above 170/110 mmHg
  • Myocardial infarction (a heart attack), stroke, or life-threatening arrhythmia (a dangerous heart rhythm) within the last 6 months
  • Unstable angina from heart failure or coronary disease
  • Prior NAION, when use would be elective
  • Hereditary retinitis pigmentosa
Key Interactions
  • Alpha-blockers (vessel-relaxing drugs such as doxazosin and tamsulosin): labeled sequence is a stable alpha-blocker first, then sildenafil at 25 mg
  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) and erythromycin or saquinavir: ritonavir 25 mg and no more than 25 mg in 48 hours; labeled start 25 mg for the others
  • CYP3A4 inducers (bosentan, rifampin): weaker effect; matters most for the three-times-daily lung-artery regimen
  • Cimetidine (Tagamet): at 800 mg; 25 mg start
  • Other blood-pressure drugs (amlodipine): standing pressure is checked after the first combined doses
  • Other PDE5 inhibitors (tadalafil, vardenafil, avanafil) and other erection treatments: combinations were not studied and may drop blood pressure further
  • Nitric-oxide-supporting supplements (L-Arginine, L-Citrulline, beet nitrate): blood-pressure drop can add up; timing separation does not remove the overlap
  • Grapefruit juice: large daily amounts; a 25 mg start is the mitigating step

Risk & Side Effects

  • High: Headache; flushing; dyspepsia; nasal congestion; color-tinge vision; drop in blood pressure
  • Medium:
  • Low: Sudden hearing loss; non-arteritic anterior ischemic optic neuropathy; melanoma; priapism
  • Speculative:

Monitoring

Marker Target Why
Blood pressure 100–120 / 60–80 mmHg Catches a low-pressure adverse effect before a nitrate or a new drug makes it dangerous
eGFR Above 90 mL/min/1.73 m² Severe impairment raises drug exposure and changes the starting dose
ALT No drug-specific target; follow the person's own baseline Liver impairment raises exposure

Cadence: Before the first dose: medication review, blood pressure, eGFR, and ALT. Seated and standing blood pressure after the first doses, at about 4 weeks, then every 6–12 months, and when another pressure-lowering or enzyme-blocking drug is added.

Qualitative Assessment

  • Erection quality during sexual stimulation, compared with the person's own baseline
  • Headache, flushing, heartburn, and nasal congestion after a dose
  • Blue-green color tinge or new blur, distinct from sudden vision loss
  • Sudden change in hearing, including ringing or dizziness with the hearing change
  • Lightheadedness on standing, especially in the first hours after a dose
  • Chest pain or marked shortness of breath with sexual activity or exercise